Home/Filings/4/0000899243-17-027028
4//SEC Filing

NeoMed Management (Jersey) Ltd 4

Accession 0000899243-17-027028

CIK 0001501697other

Filed

Nov 19, 7:00 PM ET

Accepted

Nov 20, 6:15 PM ET

Size

21.3 KB

Accession

0000899243-17-027028

Insider Transaction Report

Form 4
Period: 2017-11-20
Transactions
  • Conversion

    Common Stock

    2017-11-20+246,682246,682 total
  • Purchase

    Common Stock

    2017-11-20$10.00/sh+300,000$3,000,000867,639 total
  • Conversion

    Series D Convertible Preferred Stock

    2017-11-20952,4970 total
    Common Stock (279,079 underlying)
  • Conversion

    Common Stock

    2017-11-20+41,878288,560 total
  • Conversion

    Common Stock

    2017-11-20+279,079567,639 total
  • Conversion

    Series C Convertible Preferred Stock

    2017-11-2084,0400 total
    Common Stock (41,878 underlying)
  • Conversion

    Series B Convertible Preferred Stock

    2017-11-20552,4870 total
    Common Stock (246,682 underlying)
Transactions
  • Conversion

    Common Stock

    2017-11-20+246,682246,682 total
  • Conversion

    Series B Convertible Preferred Stock

    2017-11-20552,4870 total
    Common Stock (246,682 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2017-11-2084,0400 total
    Common Stock (41,878 underlying)
  • Conversion

    Common Stock

    2017-11-20+279,079567,639 total
  • Conversion

    Common Stock

    2017-11-20+41,878288,560 total
  • Purchase

    Common Stock

    2017-11-20$10.00/sh+300,000$3,000,000867,639 total
  • Conversion

    Series D Convertible Preferred Stock

    2017-11-20952,4970 total
    Common Stock (279,079 underlying)
Transactions
  • Conversion

    Common Stock

    2017-11-20+246,682246,682 total
  • Conversion

    Common Stock

    2017-11-20+41,878288,560 total
  • Purchase

    Common Stock

    2017-11-20$10.00/sh+300,000$3,000,000867,639 total
  • Conversion

    Series B Convertible Preferred Stock

    2017-11-20552,4870 total
    Common Stock (246,682 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2017-11-2084,0400 total
    Common Stock (41,878 underlying)
  • Conversion

    Series D Convertible Preferred Stock

    2017-11-20952,4970 total
    Common Stock (279,079 underlying)
  • Conversion

    Common Stock

    2017-11-20+279,079567,639 total
Footnotes (4)
  • [F1]The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
  • [F2]The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
  • [F3]The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
  • [F4]The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any.

Issuer

Arsanis, Inc.

CIK 0001501697

Entity typeother
IncorporatedJersey

Related Parties

1
  • filerCIK 0001722665

Filing Metadata

Form type
4
Filed
Nov 19, 7:00 PM ET
Accepted
Nov 20, 6:15 PM ET
Size
21.3 KB